BioNTech
BNTX
80.96
-0.42
-0.52%
BioNTech
US · BNTX
#801 by market cap
Listed 2019
80.96
-0.42
-0.52%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 62.02% -0.04pp
- Institutions
- 430 -2
- As of
- 2026/Q4 vs. prior period
Holder types
VC/PE Fund42.17%
Individual/Insider16.22%
Mutual Fund13.88%
Hedge Fund3.29%
Public Company1.16%
Private Company0.99%
Sovereign Wealth Fund0.29%
Government Pension Fund0.19%
Other21.78%
Top holders as of 2026-03-31
AT Impf GmbH
41.02% · 101.70M sh
Ugur Sahin
15.82% · 39.22M sh
FMR
3.95% · 9.79M sh
PRIMECAP Management Company
1.51% · 3.75M sh
Dodge & Cox
1.49% · 3.69M sh
BlackRock
0.74% · 1.83M sh
Flossbach von Storch SE
0.89% · 2.23M sh
T. Rowe Price Group, Inc.
0.53% · 1.32M sh
BNP Paribas Financial Markets SNC
0.52% · 1.28M sh
Temasek Holdings
0.50% · 1.24M sh
First Trust Advisors L.P.
0.40% · 996.31K sh
Logos Global Management, L.P.
0.41% · 1.02M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 10 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| AT Impf GmbH | -- | 41.02% |
| Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | 15.82% |
| Sierk Pötting | MD, COO & Member of Management Board | 0.22% |
| Helmut Jeggle | Independent Supervisory Board Chairman | 0.13% |
| Ozlem Tureci | Co-Founder, Chief Medical Officer & Member of Management Board | 0.05% |
| James Timothy Ryan | Chief Legal & Business Officer and Member of the Management Board | 0.00% |
| Rudolf Staudigl | Supervisory Board Member | 0.00% |
| Anja Morawietz | Supervisory Board Member | 0.00% |
| Ryan Richardson | Former Chief Strategy Officer, MD & Member of Management Board | -- |
| Salvia GmbH | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-08 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -63,209 | $92.31–95.37 |
| 2026-10-06 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -24,000 | $95.86 |
| 2026-10-05 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -93,000 | $96.81–97.23 |
| 2026-10-01 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -34,000 | $96.72–97.46 |
| 2026-09-29 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -66,000 | $98.12–98.26 |
| 2026-09-27 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -61,000 | $98.47–98.69 |
| 2026-09-23 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -69,000 | $98.99–99.40 |
| 2026-09-21 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -79,000 | $97.81–100.72 |
| 2026-09-17 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -64,000 | $96.22–98.60 |
| 2026-09-15 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -49,000 | $96.09–96.49 |
| 2026-09-13 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Private Disposition | -86,000 | $96.93–99.45 |
| 2026-09-09 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -20,500 | $96.31 |
| 2026-09-08 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -73,000 | $97.78–99.20 |
| 2026-09-03 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Automatic Disposition | -76,500 | $102.85–103.52 |
| 2026-09-02 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Intent to Sell (Form 144) | -858,209 | $103.81 |
| 2026-05-12 | Ugur Sahin | Co-Founder, CEO & Chair of the Management Board | Intent to Sell (Form 144) | -858,209 | $93.66 |
| 2026-05-11 | Sierk Pötting | MD, COO & Member of Management Board | Other Derivative Acquisition | +10,069 | -- |
| 2026-05-11 | Sierk Pötting | MD, COO & Member of Management Board | Other Derivative Acquisition | +12,586 | -- |
| 2026-05-11 | James Timothy Ryan | Chief Legal & Business Officer and Member of the Management Board | Other Derivative Acquisition | +10,069 | -- |
| 2026-05-11 | James Timothy Ryan | Chief Legal & Business Officer and Member of the Management Board | Other Derivative Acquisition | +12,586 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
BioNTech discussion 0 comments